BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.

Abstract

The clonal immunoglobulin molecule, idiotype (ID), expressed on the surface of B-cell malignancies can function as a tumor-specific antigen. BiovaxID is a patient-specific therapeutic cancer vaccine composed of the tumor idiotype conjugated to a carrier protein, keyhole limpet hemocyanin (KLH). In a Phase II clinical trial, administration of ID-KLH vaccine together with granulocyte-macrophage colony-stimulating factor to follicular lymphoma patients in complete remission induced tumor-specific cellular and humoral immunity and molecular remissions, and was associated with prolonged disease-free survival. A randomized, double-blind, Phase III clinical trial is ongoing to definitively determine the clinical benefit of BiovaxID plus granulocyte-macrophage colony-stimulating factor vaccination in patients with follicular lymphoma.

• Authors: Seung-Tae Lee, Yun-Fang Jiang, Keon-Uk Park, Alison F Woo, Sattva S Neelapu
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 7 Issue 1 Pg. 113-22 (Jan 2007) ISSN: 1744-7682 [Electronic] England
• PMID: 17150023 (Publication Type: Journal Article, Review)

Chemical References

• Cancer Vaccines
• Drugs, Investigational
• Immunoglobulin Idiotypes

Topics

• Animals
• Cancer Vaccines (immunology, therapeutic use)
• Clone Cells
• Drugs, Investigational (therapeutic use)
• Humans
• Immunoglobulin Idiotypes (therapeutic use)
• Lymphoma, Non-Hodgkin (immunology, prevention & control)